Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PDE2A | O00408 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560300 | 1.00 | LMNA (0.80) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL11311014 | 0.90 | LMNA (0.65) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL11311023 | 0.90 | LMNA (0.65) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL11311032 | 0.90 | LMNA (0.65) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL23982228 | 0.89 | LMNA (1.00) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL10607959 | 0.89 | LMNA (1.00) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL29601320 | 0.89 | LMNA (1.00) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL26030665 | 0.89 | LMNA (1.00) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL638999 | 0.89 | LMNA (1.00) | LMNATP53ADORA1ADORA2AADORA3 | |
| SCHEMBL639000 | 0.89 | LMNA (1.00) | LMNATP53ADORA1ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121721172-A | Solid phase extraction-vacuum centrifugal concentration-liquid chromatography tandem mass spectrometry detection method for chloro-product of flavor nucleotide | 浙江大学 | 2026-03-24 | — | — | CN | disclosed |
| US-20250325698-A1 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | CARIBOU BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4508211-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | Caribou Biosciences, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250027078-A1 | DNA-CONTAINING POLYNUCLEOTIDES AND GUIDES FOR CRISPR TYPE V SYSTEMS, AND METHODS OF MAKING AND USING THE SAME | CARIBOU BIOSCIENCES, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4438729-A2 | CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS | Caribou Biosciences, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024178065-A2 | CRIPPLED CORONAVIRUS: 5'-POLYU TARGETED OLIGO PREVENTS DEVELOPMENT OF INFECTIOUS VIRIONS | HOWARD UNIVERSITY (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240263180-A1 | SMALL COMPLEMENTARY NUCLEIC ACIDS, COMPOSITIONS CONTAINING THE SAME, AND METHODS FOR USE AS ANTIVIRALS | HOWARD UNIVERSITY (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4347835-A1 | SMALL COMPLEMENTARY NUCLEIC ACIDS, COMPOSITIONS CONTAINING THE SAME, AND METHODS FOR USE AS ANTIVIRALS | Howard University (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11835499-B2 | Methods of quantifying methylglyoxal-induced nucleic acid adducts | CITY OF HOPE (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023201270-A2 | THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS | CARIBOU BIOSCIENCES, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| EP-0731807-B1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030203862-A1 | Antisense modulation of MDM2 expression | ISIS PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| WO-2003048315-A2 | ANTISENSE MODULATION OF MDM2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-6166199-A | N-2 substituted purines | ISIS PHARMACEUTICALS, INC (US) | 2000-12-26 | — | — | US | disclosed |
| US-5808027-A | ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0731807-A4 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 1997-11-19 | — | — | EP | disclosed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0731807-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995014707-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203862-A1 | Antisense modulation of MDM2 expression | MDM2, TP53, DCLRE1B | LMNA 2063/4885TP53 2/4885ADORA1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.